The promise of stem cells, along with the controversy surrounding it, has made the industry a hot-button issue for many. Despite that promise, we have yet to see huge applicable benefits to humans. That could be changing. Cloning embryonic stem cells could mark a dramatic shift and improve on what is already a nascent process.

In this video, health-care analyst David Williamson discusses this breakthrough and what it means for investors interested in stem cell stocks.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.